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Summary 
In Alzheimer's disease brains, more than 90% of pyra- 
midal neurons in lamina V and 70% in lamina III dis- 
played 2- to 5-fold elevated levels of cathepsin D (Cat 
D) mRNA by in situ hybridization compared with neuro- 
logically normal controls. Most of these cells appeared 
histologically normal. The less vulnerable nonpyrami- 
dal neuron population in lamina IV had relatively nor- 
mal message levels. Neuronal populations expressing 
more Cat D mRNA also displayed quantitatively in- 
creased Cat D immunoreactive protein. Cat D mRNA 
expression was only moderately increased in astro- 
cytes. Degenerating neurons exhibited intense immu- 
noreactivity but lowered Cat D mRNA levels. The up- 
regulation of Cat D synthesis and accumulation of 
hydrolase-laden lysosomes indicate an early activa- 
tion of the endosomal-lysosomal system invulnerable 
neuronal populations, possibly reflecting early regen- 
erative or repair processes. These abnormalities also 
represent a basis for attered regulation of amyloid pre- 
cursor protein processing. 
Introduction 
The lysosomal system is composed of several distinct and 
dynamically interacting vesicular compartments that are 
major sites for intracellular protein turnover and the limited 
proteolytic processing of certain proteins (deDuve et al., 
1955). Acid hydrolases of different enzyme classes, which 
are optimally active at acidic pH, mediate these processing 
events. The biosynthesis of lysosomes begins with the de 
novo synthesis of lysosomal hydrolases and membrane 
glycoproteins in the endoplasmic reticulum, followed by 
posttranslational modification and packaging in the Golgi 
apparatus. In a subsequent series of signaling and sorting 
processes, lysosomal enzymes bind to high affinity man- 
nose-6-phosphate receptors (MPR) and exit the Golgi ap- 
paratus via coated vesicles (for review, see Kornfeld and 
Mellman, 1989; Geuze et al., 1988; Gruenberg and How- 
ell, 1989). These Golgi-derived vesicles containing na- 
scent lysosomal hydrolase are selectively transported to 
a prelysosomal compartment, where the enzyme is disso- 
ciated from the receptor by acidification of the compart- 
ment (Brown et al., 1986; Dahms et al., 1989; Griffiths et 
al., 1990). 
The classical literature (deDuve and Wattiaux, 1966) 
categorizes lysosomes into three morphologically distinct 
compartments containing catalytically competent hydro- 
lases. These compartments include primary lysosomes car- 
rying only newly synthesized hydrolase, secondary lyso- 
somes composed of enzyme and internalized material 
undergoing digestion (e.g., autophagic vacuoles, multive- 
sicular/multilamellar bodies, and dense bodies), and ter- 
tiary lysosomes (e.g., lipofuscin) composed of residual, 
undigested material. More recent studies, however, reveal 
greater complexity, including the existence of distinct early 
and late endosomal compartments in addition to mature 
lysosomes (Dahms et al., 1989; Griffiths et al., 1990). Acid 
hydrolases are abundant in late endosomes and mature 
lysosomes and are also present in lower amounts and in 
active form within early endosomes (Rodman et al., 1990; 
Diment et al., 1988; Lemansky et al., 1987; Bowser and 
Murphy, 1990). In most cells, a small percentage of hy- 
drolase escapes the receptor-mediated intracellular tar- 
geting to lysosomes and is routed through the secretory 
pathway (Hasilik, 1992). Late endosomes undergo both 
fission and fusion with other endocytic corn partments and 
autophagic vacuoles, providing a link between endocytic 
and autophagic pathways (Gorden and Seglen, 1988; 
Deng et al., 1991). 
Immunocytochemical studies (Cataldo et al., 1990, 
1994; Nixon et al., 1992, 1993; Bernstein et al., 1992; 
Nakamura et al., 1991) of lysosomal hydrolases have dem- 
onstrated abnormalities of the lysosomal system at early 
and late stages of AIzheimer's disease pathogenesis. In- 
creased levels of lysosomal hydrolases of different enzyme 
classes and accumulation of acid hydrolase-containing 
compartments in at-risk populations of normal-appearing 
neurons precede the earliest known intracellular histo- 
pathological features of the disease and worsen as overt 
signs of degeneration appear (Nixon et al., 1992; Cataldo 
et al., 1994). Following cell lysis, the liberation of cathepsin 
D (Cat D) and many other lysosomal hydrolases within 
secondary and tertiary lysosomes accounts for the abnor- 
mal extracellular presence of these enzymes in associa- 
tion with ~-amyloid deposits (Cataldo et al., 1994). The 
persistence of acid hydrolase deposits in the extracellular 
space is, to our knowledge, a pathological phenomenon 
selectively related to AIzheimer's pathogenesis and other 
conditions associated with I~-amyloidogenesis (Nixon and 
Cataldo, 1991; Nixon et al., 1992; Villanova et al., 1993). 
Additional changes in hydrotase expression may occur 
secondarily in astrocytes in Alzheimer's disease (Diedrich 
et al., 1991 ; Nakamura et al., 1991); however, histochemi- 
cal, immunologic, and ultrastructural evidence indicates 
that degenerating neurons (Cataldo et al., 1990, 1994; 
Nixon and Cataldo, 1991; Nixon et al., 1992) and their 
processes are the principal sources of extracellular hy- 
drolase in plaques of Alzheimer's brain parenchyma. Most 
recently, we have found that Cat D levels in ventricular cere- 
brospinal fluid averaged 4-fold higher in Alzheimer's pa- 
tients than in a control group of patients with Huntington's 
disease and other neurodegenerative diseases (Schwagerl 
and Nixon, unpublished data). 
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Figure 1. Increased Expression of Cat D 
mRNA in At-Risk Neocortical Pyramidal Neu- 
rons from Alzheimer's Brains 
(A and B) In the prefrontal cortex of control 
brains, pyramidal neurons in laminae III and V 
(arrows) displayed modestly high levels of Cat 
D mRNA within the soma and proximal den- 
drites. The sense Cat D RNA probe, which 
served as a negative control, yielded negligible 
hybridization signal (inset in [B]). 
(C and D) In Alzheimer's brains, the majority 
of neurons in the same populations exhibited 
increased levels of specific Cat D mRNA signal 
(arrows). Signal evels were the densest in the 
cell body and proximal dendrites with lower lev- 
els in the basal dendrites. 
(E and F) Several of the same at-risk neurons 
(arrows) in AIzheimer's brain containing dense 
Cat D mRNA signal expression (E) appear mor- 
phologically normal in a serial adjacent Nissl- 
stained section (F). 
Bars, 50 p~m (A and C); 10 p.m (B and D); 20 
~m (E and F). 
Beyond the abnormal phosphorylation oftau protein and 
formation of neurofibrillary tangles in some affected neu- 
rons, little is known about the early intraceliular events 
associated with Alzheimer's disease. In addition to provid- 
ing information about these events, the possibility that the 
endosomal-lysosomal pathway in vulnerable neurons 
may be activated in Alzheimer's disease may have other 
implications for the pathogenesis of the disease. A major 
route of amyloid precursor protein (APP) processing and 
degradation is through the endosomal-lysosomal path- 
way (Estus et al., 1992; Golde et al., 1992; Siman et al., 
1993; Caporaso et al., 1992; Haass et ai., 1992; Cole et 
al., 1992). Although the site of normal 13-amyloid peptide 
(AI3) generation is still unresolved, endosomal (Koo and 
Squazzo, 1994; Haass et al., 1993; Haass and Selkoe, 
1993; Shoji et al., 1992) or late Golgi compartments (Bus- 
caglio et al., 1993; Haass et al., 1993) have been proposed 
on the basis of indirect evidence. Although t e responsible 
proteases are unknown, several cathepsins, some of 
which are known to be present in each of these compart- 
ments (Hasilik, 1992; Diment et al., 1988), are among the 
candidates (Abraham et al., 1992; Tagawa et al., 1992; 
Ishiura, 1991; Ishiura et al., 1990; Schonlein et al., 1993; 
Ladror et al., 1994; Shi et al., 1994). APP is also metabo- 
lized in lysosomes to smaller fragments containing the 
complete AI3 domain (Estus et al., 1992; Caporaso et al., 
1992), which could be neurotoxic (Yankner et al., 1989; 
Neve et ai., 1992) or be an additional potential source of 
AI~, especially if lysosomal system function were disturbed 
(Cataldo et al., 1990, 1994; Nixon et al., 1992; Tagawa et 
al., 1992). Finally, the physiologic function and metabolism 
of apolipoprotein E, a major risk factor in Alzheimer's dis- 
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Figure 2. Cat D rnRNA in Nonpyramidal Neu- 
rons 
Nonpyramidai neurons from lamina IV (aster- 
isks) of the prefrontal cortex of age-matched 
control (A) and Alzheimer's brains (B) display 
similar Cat D mRNA levels (arrows in insets). 
Normal message l vels in these neurons con- 
trast with the higher levels in earby pyramidal 
neurons in laminae III and V in Alzheimer's 
brains (arrowheads in [B]). Bars, 50 ~m (A and 
B); 20 ~m (insets). 
ease (Corder et al., 1993; Strittmatter et al., 1993), de- 
pends on the endosomal-lysosomal system (Ye et al., 
1993). 
To test the hypothesis that t~e endosomal-lysosomal 
system is up-regulated early in Alzheimer's pathogenesis 
and to examine whether previous observations of abnor- 
mal lysosome hydrolase accumulation in neurons reflect 
decreased turnover or increased synthesis of lysosomal 
Ilydrolases, we measured the levels of expression of Cat 
D mRNA by in situ hybridization and Cat D protein levels by 
immunocytochemistry. Our results show that substantial 
increases in Cat D content detected immunocytochemi- 
cally within at-risk populations of neurons in Alzheimer's 
brains are associated with marked up-regulation of Cat D 
gene expression in these same cell groups. 
Results 
Expression of Cat D-Specific mRNA in Neocortical 
Neurons from Normal Human Brain 
Light microscopic inspection of hybridized tissue sections 
from the prefrontal cortices of control brains displayed a 
distribution of specific Cat D mRNA expression (Figure 1) 
consistent with that of immunoreactive Cat D seen in our 
previous cytochemical studies (Cataldo et al., 1994; Ca- 
taldo and Nixon, 1990; Nixon et al., 1992). Cat D mRNA 
was most prominently localized in pyramidal neurons 
throughout all layers of the cortical mantle and varied little 
among neurons of different sizes (Figure I ; also see Figure 
3). Within these neurons, Cat D signal was high in neuronal 
cell bodies, low in the proximal dendrites (Figure 1), and 
undetectable in axons. Cat D m RNA levels were relatively 
low in nonpyramidal neurons of the prefrontal cortex (see 
below). Somewhat higher levels were detected in astrocytes 
identified by their nuclear size, shape, and chromatin pat- 
tern; however, compared with pyramidal neurons, astro- 
cytes contained much lower Cat D message levels. Cat 
D signal was negligible to absent in sections from the same 
brain regions hybridized with the sense Cat D cRNA probe 
(Figure 1). No differences were observed between the 
quality and quantity of mRNA expression detected using 
biotin and digoxigenin-labeled Cat D RNA probes. 
Markedly Increased Cat D mRNA Levels in At-Risk 
Neuronal Populations from Alzheimer's Brains 
Hybridized tissue sections from AIzheimer's brains exhib- 
ited prominent increases in specific Cat D mRNA signal 
in nearly all of the pyramidal neurons within layers III and 
V (Figure 1). The signal was exclusively intracellular and 
densest within the cell body and proximal dendrites, but 
also appeared in low levels within the basal dendrites. 
Most neurons expressing very high levels of signal expres- 
sion displayed no evidence of atrophy or chromatolysis. 
In serial adjacent sections from Alzheimer's brains stained 
with Nissl (Figure 1), silver, or thioflavin S stains, nonpyra- 
midal neurons in cortical lamina IV had levels of Cat D 
mRNA that, by light microscopic inspection, were equiva- 
lent to the levels observed in age-matched control brains 
(Figure 2). Consistent with other investigators (Diedrich et 
al., 1991; Nakamura et al., 1991; Bernstein et al., 1989, 
1992), we detected an increased expression in the levei 
of Cat D mRNA within activated astrocytes by qualitative 
estimation. Modest increases in the level of glial Cat D 
signal were exhibited in both white and gray matter; how- 
ever, Cat D mRNA levels in pyramidal neurons consider- 
ably exceeded those in astrocytes, in accord with previous 
immunocytochemical studies (Cataldo et al., 1990). 
To estimate the magnitude of the message increase and 
the proportion of the pyramidal cell population affected, 
we used computer-assisted microdensitometry to mea- 
sure the density of Cat D mRNA signal in 125 individual, 
at-risk pyramidal neurons in neocortical aminae layer Ill 
and separately in lamina V from five AIzheimer's brains 
and five control brains matched with respective postmor- 
tem interval and age of the individual. Greater than 94% 
of the pyramidal neurons in layer V and greater than 70% 
in layer III of the Alzheimer's brains displayed Cat D mRNA 
message densities that were 2 SD higher than the mean 
values measured in neurons of comparable size in control 
brains (Figure 3A). Small, medium, and large size pyrami- 
dal neurons displayed mRNA increases of similar magni- 
tude. Elevations of Cat D mRNA levels ranged from 1.5- 
to 5-fold and for the whole population, averaged 2.5-fold 
higher than the mean value for the population of neurons 
analyzed in control cases (p < .001). 
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Figure 3. Densitometry of Cat D mRNA and 
Protein in Control and Alzheimer's Brains 
(A) Microdensitometric measurements of 
mRNA in hybridized tissue s ctions howed an 
average 2.5-fold increase in the magnitude of 
mRNA levels in neurons of Alzheimer's (closed 
circles) brains compared with the same popula- 
tions of neurons from control brains (open tri- 
angles). Increases in mRNA message densities 
greater than 2 SD over the mean of control 
neurons (dotted line) were displayed in 70O/o - 
94% of at-risk pyramidal neocortical laminae III 
and V of Alzheimer's brains with no significant 
differences in cross sectional areas. Northern 
blot analyses (inset) performed on homoge- 
nates of the prefrontal cortices from Alzhei- 
mer's (designated A in inset) and age-matched 
control (designated C in inset) brains howed 
an increase in the relative l vels of Cat D m RNA 
from AIzheimer's brains that coincided with the 
levels of Cat D mRNA expression detected by 
in situ hybridization. 
(B) The majority of neocortical pyramids in lami- 
nae III and V from Alzheimer's brains (closed 
circles) exhibited increased levels of Cat D im- 
munoreactivity per cross-sectional rea corn- 
pared with age-matched controls (open triangies) in sections examined by semiquantitative microdensitometric analyses. Increases in the cytochemi- 
cal density of Cat D parallel the increases in Cat D mRNA levels within the same neuronal populations. Dotted line represents control mean 
density. 
Northern blot analyses on brain homogenates from the 
prefrontal cortices of five Alzheimer's and five control 
brains confirmed the presence of increased levels of Cat 
D mRNA in Alzheimer's brains compared with their age- 
matched counterparts (Figure 3A). Relative Cat D levels 
were elevated an average of 35% in Alzheimer's cases 
(p < .05). Because of the extensive fallout of pyramidal 
neurons in the Alzheimer's cases and the substantial con- 
tribution of nonneuronal cells and unaffected neurons to 
the baseline Cat D mRNA levels, it was not unexpected 
that Northern blot analysis would underestimate the Cat 
D mRNA increase exhibited by the remaining pyramidal 
neurons and detected by in situ hybridization. Ribosomal 
Ioadings were identical. Hybridization with probes for other 
hydrolases (i.e., cathepsin B and hexcsaminidase A [data 
not shown]) did not reveal cross-hybridization with the 18S 
ribosomal species; however, if it did occur, because ribo- 
somal loading was identical, cross hybridization would 
have added an equal amount to the signals obtained from 
Alzheimefs and control brains and would contribute to 
an underestimation of the differences between the two 
groups. The use of Northern blot analyses in this study 
was not intended to supply major quantitative vidence 
but to confirm that the Cat D probe hybridized well to a 
band of the expected size. 
Abnormally High Cat D mRNA Expression Is 
Associated with Increased Cat D Content in 
Pyramidal Neurons from Alzheimer's Brains 
Neocortical sections serially adjacent o those used in the 
in situ hybridization studies were immunolabeled with an 
antiserum against human brain Cat D. As in previous stud- 
ies, Cat D immunoreactivity in he•cortical pyramids from 
layers III and V was increased to varying extents in lyso- 
somal compartments that accumulate markedly within the 
soma, dendrites, and axon hillock (Figure 4 and see Figure 
1; for further details, see Cataldo et al., 1994; Nixon et 
al., 1992). Semiquantitative microdensitometric analyses 
of immunocytochemical reaction product indicated that 
the majority of pyramidal neurons in either laminae III or V 
in Alzheimer's neocortex displayed abnormally increased 
levels of immunoreactivity per cross-sectional perikaryal 
area compared with the same groups of neurons from 
the control brains. The mean density of immunoreaction 
product in neurons in the Alzheimer group averaged 1.5- 
fold higher than the control value (p < .001). The mean 
cross-sectional area of pyramidal neuron perikarya in AIz- 
heimer's brains did not differ significantly from that in con- 
trol brains (see Figure 3B; data not shown). Increases in 
the intensity of Cat D immunostaining paralleled the in- 
crease in Cat D mRNA signal in pyramidal neurons from 
either layers III or V in Alzheimer brains (Figure 4) with one 
exception. Neurons in advanced stages of degeneration 
contained massive amounts of Cat D immunoreactivity 
but in many instances, exhibited lower than normal Cat 
D mRNA signals. Nonpyramidal neurons in neocortical 
lamina IV displayed immunoreactive Cat D content similar 
to their control counterparts. Although we have not as yet 
analyzed Cat D mRNA levels in other neurodegenerative 
disorders such as Pick's disease and Huntington's dis- 
ease, we have found that neurons containing Pick's bodies 
or at-risk neuronal populations in stage IV Huntington's 
disease do not display elevated levels of Cat D immunore- 
activity until the very end stages of cell death (Figure 4). 
Cat D mRNA Expression in Relation to 
Alzheimer's Neuropathology 
Silver staining of adjacent tissue sections from the Alzhei- 
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Figure 4. Cat D mRNA Expression Correlates with Cat D Content 
Tissue sections from the prefrontal cortex of Alzheimer's brains immunolabeled with anti-Cat D antiserum (A) show an increase in Cat D-positive 
lysosomal compartments within layer III pyramids (arrow). Serial adjacent issue sections displayed a parallel increase in specific Cat D signal 
expression within the same neurons and/or population of neurons (arrow in [B]). In this group of neurons, both Cat D immunoreactivity and signal 
expression accumulated inthe same intracellular regions. Early alterations in Cat D immunoreactivitywere not prominent in intact neurons containing 
Pick's bodies (left inset) and at-risk neuronal populations from late-stage Huntington's disease (right inset) brains. Bars, 10 I~m. 
mer's cases showed that neu rofibrillary tangles were pres- 
ent in only 5%-18% of the neurons in layers III and V that 
contained elevated levels of both Cat D mRNA expression 
and immunoreactivity (data not shown). Degenerating 
neurons and their processes are a major source of extra- 
cellular Cat D associated within senile plaques (Cataldo 
et al., 1990, 1994; Nixon et al., 1992). We were unable, 
however, to detect the presence of Cat D-specific mRNA 
within most dying neurons associated with senile plaques 
or in Cat D-positive senile plaques identified by silver 
staining (data not shown). Intact pyramidal neurons dis- 
playing elevated Cat D mRNA levels were frequently in 
close proximity with, but were not part of, the senile 
plaques. Reactive astrocytes containing high Cat D mRNA 
levels were observed at the crown of senile plaques periph- 
eral to the location of most of the Cat D immunoreactivity 
present in the plaque. 
Discussion 
The EndosomaI-Lysosomal System Is 
Up-Regulated in Alzheimer's Disease 
Our results show that nearly all pyramidal neurons from 
layers III and V of Alzheimer's prefrontal cortex exhibit 
abnormally elevated Cat D mRNA levels, which average 
2- to 3-fold higher than their counterparts in age-matched 
normal control neocortex. By contrast, the less vulnerable 
population of nonpyramidal neurons in lamina IV exhibited 
relatively normal Cat D expression and immunoreactive 
content. Increased hydrolase synthesis, therefore, at least 
partly explains the marked accumulation of Cat D and 
probably the increased content of many other acid hy- 
drolases previously observed in pyramidal neurons inAIz- 
heimer's brains (Cataldo et al., 1990, 1994; Nixon and 
Cataldo, 1991 ; Nakamura et al., 1991). In this regard, addi- 
tional Northern blot analyses for Cat B, which is present 
by immunocytochemistry in neurons to a much greater 
extent than astrocytes, showed increases of greater 
magnitude in Alzheimer's brain compared with controls 
(A. M. C. and R. A. N., unpublished data). In the same 
neuron populations, hydrolase-laden vesicular compart- 
ments accumulate and have been shown by double-label 
confocal imaging to be primarily Cat D immunoreactive 
secondary lysosomes or prelysosomal compartments, 
rather than lipofuscin (A. M. C. and R. A. N., unpublished 
data). This agrees with other findings that lipofuscin, a 
relatively nonspecific concomitant of neurodegeneration, 
is only modestly increased in Alzheimer's disease (Mann 
et ai., 1984a, 1984b). Taken together, these findings are 
strong evidence that the endosomal-lysosomal system is 
abnormally activated in neuronal populations at risk to de- 
generate in Alzheimers disease. The observation that acti- 
vation is evident in an extremely high percentage of cell 
populations and develops before neurofibrillary tangles 
or other signs of degeneration appear implies that these 
changes are an early stage of metabolic compromise in 
vulnerable neuronal populations. 
Early Endosomal Up-Regulation in Relation to 
Alzheimer's Pathogenesis 
Changes in acid hydrolase xpression reflect the function- 
ing of several different compartments of the endosomal- 
lysosomal system. Cat D and other hydrolases are abun- 
dant not only in lysosomes but in prelysosomal compart- 
ments, including early and late endosomes, where many 
hydrolases may exist in both proenzyme and mature forms 
(Lemansky et al., 1987; Riederer et al., 1994; Erickson 
and Blobel, 1983). Although these various acidic vesicular 
compartments have certain distinguishing biochemical 
and morphotogic features, acid hydrolases cleave proteins 
within each of these compartments (Diment et al., 1988; 
Bowser and Murphy, 1990; Rodman et al., 1990; Leman- 
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sky et al., 1987). Acid hydrolases, like Cat D, are also 
present to some extent in the secretory pathway, although 
their activity is not known (Hasilik, 1992). Studies of non- 
neuronal cells indicate that late endosomes and lyso- 
somes are sites of convergence of the endocytic (hetero- 
phagic) and autophagic pathways (Gordon et al., 1992; 
Deng et al., 1991). Therefore, up-regulation of hydrolase 
synthesis and lysosome biogenesis may reflect acceler- 
ated endocytosis, autophagy, or both. Each of these re- 
sponses has been reported in relation to states of nutri- 
tional deprivation and a few neurodegenerative states (for 
review, see Nixon and Cataldo, 1993); however, endoso- 
mal-lysosomal system activation, manifested by second- 
ary lysosome accumulation, is not an essential concomi- 
tant of either apoptotic or necrotic cell death (Nixon and 
Cataldo, 1993). The nature and magnitude of the lyso- 
somal response in Alzheimer's disease and Down's syn- 
drome are, in fact, uncommonly seen as features of neu- 
ronal cell death in many neuropathologic onditions (Nixon 
and Cataldo, 1993). In this regard, corresponding immuno- 
cytochemical studies of other neurodegenerative dis- 
eases, including Huntington's disease, multiple sclerosis, 
amyotrophic lateral sclerosis, and progressive supranu- 
clear palsy (Nixon et al., 1992; li et al., 1993; A. M. C. 
and R. A. N., unpublished data) indicate relatively minor 
lysosomal accumulation in affected neuronal populations, 
even as these neurons are degenerating. Even less com- 
monly described is the persistence of lysosomal compart- 
ments in the extracellular space as hydrolase-laden eu- 
rons degenerate (Cataldo et al., 1994). To our knowledge, 
this feature has not been observed in conditions other than 
those in which 13-amyloid isdeposited, and it therefore may 
be a useful diagnostic feature of the degenerative process 
in Alzheimer's disease and related ~-amyloidoses. 
Although their triggering mechanisms are not well un- 
derstood, autophagy and endocytosis are responses 
expected in cells chronically attempting to regenerate, 
catabolize injured membranes, and synthesize new mem- 
branes. Membrane dysfunction in Alzheimer's disease is 
suggested by alterations in membrane fluidity (Zubenko 
et al., 1987; Hajimohammadreza nd Brammer, 1990), 
lipids (Farooqui et al., 1988; Pettegrew, 1989), lipolytic 
enzymes, and membrane and membrane-associated pro- 
teins (Bosman et al., 1991), including mutations of APP 
(Castano et al., 1991; Goate et al., 1991). Moreover, the 
extensive axon terminal degeneration and dendritic dys- 
trophy in Alzheimer's disease, which may precede mor- 
phologic changes in neuronal perikarya, implies the break- 
down and replacement of large areas of membrane 
surface. Accelerated membrane trafficking to and from the 
periphery may account for the easily detected endosomal- 
lysosomal system up-regulation in perikarya in a very high 
percentage of otherwise normal-appearing pyramidal neu- 
rons that display prominent accumulations of lysosomal 
compartments at the perikaryal level. The suspected im- 
portance of the apolipoprotein E (Apo E) genotype as a 
risk factor in Alzheimer's disease (Corder et al., 1993; 
Strittmatter et al., 1993) could also relate to its function 
in cholesterol transport and membrane synthesis (Ser- 
ougne et al., 1976; Mahley, 1988), which requires endoso- 
mal-lysosomal system activity (Ye et al., 1993). Apo E 
synthesis in astrocytes and Apo E uptake by neurons are 
markedly up-regulated in response to neuronal injury (Die- 
drich et al., 1991; Muller and Minwegan, 1985; Poirer et 
al., 1993), presumably to provide cholesterol for new mem- 
brane synthesis and regenerative processes (Mahley, 
1988). Finally, aging, a major risk factor in AIzheimer's 
disease, is associated with an additional modest up- 
regulation of the lysosomal system (Matus and Green, 
1987; Lajtha et al., 1992; Nakamura et al., 1989), which 
would superimpose on the disease-related alterations of 
this system observed in our studies. 
EndosomaI-Lysosoma! System Activation 
and APP Processing 
Given the known localization of acid hydrolases in early 
and late endosomes as well as lysosomal compartments 
(Bowser and Murphy, 1990; Rodman et al., 1990; Leman- 
sky et al., 1987), up-regulation of the endosomal-lyso- 
somal system is likely to influence the processing of APP. 
Lysosomes are a major site for the intracellular turnover 
of APP (Cole et al., 1992; Golde et al., 1992; Caporaso 
et al., 1992; Haass et al., 1992), and regulated sorting of 
APP to lysosomes may determine functional evels of APP 
in cells as well as influence levels of secreted APP (Sam- 
bamurti et al., 1992; Golde et al., 1992; Caporaso et al., 
1992). Soluble forms of A~ 1-40, and possibly AJ~ 1-42 
are normally secreted from certain cells (Shoji et al., 1992; 
Haass et al., 1992), and indirect evidence exists that A~ 
1-40 may be generated normal!y in a late-Golgi or endoso- 
real compartment by noncysteine proteases (Buscaglio et 
al., 1993; Haass et al., 1993; Koo and Squazzo, 1994). 
Although the responsible proteases have not been defini- 
tively identified, certain cathepsins cleave model peptide 
sequences of APP at sites relevant o this process. Cat 
D was found recently to generate the N terminus in AI~ 
from a model peptide substrate (Ladror et al., 1994), and 
this process was accelerated more than 70-fold when the 
two amino acid residues corresponding to the double mu- 
tation in a Swedish family with early-onset familiar Alzhei- 
mer's disease (Almquist et al., 1993; Lilius and Lannfelt, 
1994) were substituted. Cathepsin S has also been impli- 
cated indirectly in A[3 formation (Shi et al., 1994). APP 
processing within post-Golgi or mature lysosomal com- 
partments also represents a route to the generation of 
potentially amyloidogenic fragments of APP containing 
the entire A~ domain (Caporaso et al., 1992; Siman et al., 
1993; Estus et al., 1992), some of which may be neurotoxic 
when expressed in high amounts (Yankner et al., 1989; 
Neve et al., 1992; Hayashi et al., 1992). It should also 
be considered that the trafficking and processing of APP 
could change when ceils are stressed (Baskin et al., 1991) 
or injured. Up-regulated hydrolase synthesis, for example, 
might be expected to increase levels of certain enzymes 
in vesicular compartments that normally contain negligible 
or minimal evels, thereby greatly accelerating some nor- 
mal or alternative processing events. Finally, in AIzhei- 
mer's disease, enzymatically competent lysosomal hy- 
drolases are found in abnormal extracellular locations 
within both diffuse and classical amyloid-containing senile 
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plaques (Cataldo et al., 1990, 1994). Dysregulation of nor- 
mal processing pathways in degenerating neurons has 
been proposed as an additional route that may be respon- 
sible for the generation of AI3 or amyloidogenic fragments 
in these lesions (Cataldo et al., 1994; Nixon and Cataldo, 
1991). 
Relationship of Cat D Expression to Endstage 
Alzheimer's Pathology 
Degenerating neurons or their processes are a major 
source of extracellular Cat D and the various other ly- 
sosomal hydrolases and hydrolase activities in senile 
plaques (Cataldo etal . ,  1990; 1994). However, the most 
intensely Cat D immunoreactive degenerated neurons in 
the plaques exhibit lowered Cat D mRNA levels, owing to 
depletion or breakdown of RNA accompanying the degen- 
erative process and to the scavenging responses of infiltra- 
tive cells. Reactive gliosis consisting of increased num- 
bers of hypertrophic astrocytes and the presence of 
reactive astrocytes at the crown of both cored and uncored 
senile plaques is a characteristic feature of Alzheimer's 
neuropathology (Beach et al., ~989; Dully et al., 1982). 
Our results are consistent with earlier findings (Diedrich 
et al., 1991) that some astrocytes express higher levels 
of Cat D mRNA in Alzheimer's brain. Increased lysosomal 
hydrolase expression in these cells is observed in various 
degenerative states, suggesting that lysosomal system 
up-regulation may accompany the hyperplastic/hypertro- 
phic response of astrocytes (Massacesi etal., 1988; Bever 
et al., 1989; Bernstein et al., 1992; Nakanishi et al., 1993). 
Several lines of evidence indicate, however, that astrocytes 
are an additional but minor source of the extracellular hy- 
drolases present in senile plaques compared with neu- 
rons. In cytochemical experiments involving double- 
labeling techniques with glial fibrillary acidic protein and 
Cat D antisera, astrocyte cell bodies were most abundant 
at the crown of amyloid-containing senile plaques but were 
not present in the central portions of the plaque where 
Cat D immunoreactivity was highest (Cataldo et al., 1990). 
The molecular layer of the prefrontal cortex, for example, 
contains numerous nodules of strongly Cat D-positive 
astrocytes, which are not associated with extracellular hy- 
drolase deposits (Cataldo et al., ~ 990). Moreover, cathep- 
sins H and G, proteases abundant in gila but not neurons, 
were not detectable extracellularty in senile plaques. Con- 
versely, acid hydrolases that were abundant in neurons 
but absent or at much lower levels in glia (e.g., Hex A and 
cathepsin B) were well represented in plaques extracel- 
lularly. 
Experimental Procedures 
Tissue 
Postmortem brain tissue from the prefrontal cortex (Brodmann area 
10) of ten individuals with the probable clinical diagnosis of AIzheimer's 
disease and nine age-matched (62-78 years) neurologically normal 
controls were used in this study. Tissue was procured from the Brain 
Tissue Resource Centers at McLean Hospital (Belmont, MA) and the 
University of Massachusetts Medical School (Worcester, MA) and the 
Neuropathology Core Facility of the Massachusetts Alzheimer's Dis- 
ease Research Center (Massachusetts General Hospital, Boston, MA). 
Control brains ranged from 1200 to 1350 g in weight and exhibited 
no gross anatomical pathology and only minimal histopathological 
changes (0-3 neuritic plaques per low power field; 0-6 neurofibrillary 
tangles per low power field). 
The presence and magnitude of neurodegeneration a d neurofibril- 
lary histopathology were confirmed on adjacent, serial paraffin sec- 
tions from all brains analyzed using Nissl and Bielschowsky silver 
stains, and the diagnosis of Alzheimer's disease was established by 
the Consortium to Establish a Registry of Alzheimer's Disease criteria 
(Mirra et al., 1991). The presence of the 13-amyloid protein was detected 
histologically using thioflavin S staining. Postmortem interval for all 
brain tissue employed was 0-6 hr, with a total fixation time of 2 weeks 
or less. 
Antibodies 
Immunocytochemical studies were performed on paraffin or vibratome 
sections using an antiserum directed against human brain CAT D. 
This antibody was raised in sheep, and its immunospecificity was con- 
firmed as described in previous studies (Nixon and Marotta, 1984; 
Cataldo et al., 1990). 
Immunocytochemistry 
Hydrolase immunoreactivity was demonstrated using a modification 
of the avidin-biotin technique of Hsu et al. (1981) and Vectastain kits 
(Vector Laboratories, Inc., Burlingame, CA), with diaminebenzidine as 
the chromagen. Negative controls consisted of tissue sections incu- 
bated in preimmune antisera or in the absence of primary antiserum. 
Source and Labeling of Probes 
cDNA for human Cat D was generously provided by Dr. P. Faust (1985). 
Isolation of the plasmid DNA was performed by the general method 
outlined by Maniatis et al. (1989). The Cat D clone, CDpSP64, which 
contained a 2.2 kb cDNA, was inserted into a pSP64 vector and ori- 
ented so that the SP6 promotor produced antisense Cat D cRNA. For 
the purpose of obtaining an RNA control probe, the Cat D insert was 
subcloned in the PGEM2 vector system (Promega) oriented so that 
transcription by T7 polymerase yielded a sense RNA probe. 
The CDpSp64 was linearized with Kpnl so that the SP6 promotor 
would produce approximately 400 bp antisense cRNA. The labeled 
RNA was produced in a 100 p.I solution containing 40 mM Tris-HCI 
(pH 7.5), 6 mM MgCI2, 2 mM spermidine, 10 mM NaCI, 20 mM DTT, 
1 mM ATP, 1 mM GTP, 1 mM CTP, and 1 mM either biotinylated or 
digoxigenin conjugated UTP, together with 0.1 mM UTP, 100 U of 
RNAsin ribonuclease inhibitor, 2 v.g linearized plasmid DNA, and 200 
U of SP64 RNA polymerase and incubated for 90 min at 37°C. After 
incubation, 0.38 v 10 N ammonium acetate, 2.5 v ethanol, and 1 ~l of 
concentrated glycogen (Boehringer-Mannheim) was added, and after 
incubation at 4°C for 30 rain, the precipitate was recovered by centri- 
fuging for 10 min at 10,000 x g. The RNA was redissolved in 100 p.I 
of 1 M ammonium acetate and reprecipitated as described above. In 
some cases, the DpSP64 was cut with EcoR1, and the resultant 2.2 
kb RNA product was digested to an average size of 400 bp by limited 
alkaline hydrolysis (Cox et al., 1984). 
In Situ Hybridization and Detection 
The protocol employed for in situ hybridization and detection employed 
a modified hapten affinity cytochemical technique using biotin- 
streptavidin and digoxigenin antibodies (Boehringer-Mannheim Bio- 
chemicals, Mannheim, Germany) and the kit detection system of Gibco 
BRL (Life Technologies, Inc., Gaithersburg, ME)). Deparaffinized sec- 
tions were washed in phosphate-buffered saline (PBS; pH 7.4) twice 
for 5 min each and transferred to 0.2 M Tris-HCL plus glycine (pH 
7.4) for 10 min. After a brief rinse in PBS, slides were incubated in 
predigested (40 rain) proteinase K (40 p~g/ml) for 10 min at 37°C. Sec- 
tions were immersed for 1 min in 4% paraformaldehyde/PBS (pH 7.4) 
at room temperature, rinsed for 5 min in PBS, and dehydrated through 
a series of alcohols. Tissue sections selected as negative controls 
were incubated for 45 min at 37°C in RNAase (20 ~g/ml) or were 
hybridized with a sense RNA probe. Positive control slides for the 
biotinylated RNA probes were included in the system and consisted 
of paraffin-embedded HeLa cells infected with adenovirus type 2. The 
slides were hybridized in sealed humidity chambers for 4-5 hr at 42°C. 
Following hybridization, the slides were rinsed in 1 M SSC and incu- 
bated in RNAse for 30 min at 37°C. Tissue sections then were rinsed 
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three times briefly in 0.2 M SSC and again in 0.2 M SSC for two 10 
rain washes. Sections were blocked for 20 min at room temperature 
and incubated for 1-2 hr in either the streptavidin-alkaline phospha- 
tase conjugate or digoxigenin-alkaline phosphatase conjugate. Slides 
were rinsed twice for 15 rain each and then briefly for 5 rain in alkaline 
substrate buffer containing Trizma base, sodium chloride, and magne- 
sium chloride (pH 9.5), followed by incubation in the reaction mixture 
(200 Id nitroblue tetrazolium and 166 ~1 4-bromo-5-chloro-3-indolyl- 
phosphate/50 ml alkaline substrate buffer) for 1-3 hr at 37°C. Color 
development was stopped by rinsing sections in deionized water. The 
tissue was dehydrated through ethanols, air dried, and coverslipped 
with an aqueous mounting medium. All solutions were prepared in 
diethyl pyrocarbonate-treated autoclaved water and passed through 
sterile 0.22 p,m filters before use. 
Northern Blot Analysis 
Total cytoplasmic RNAs were isolated with TRI Reagent (Molecular 
Research Center, Cincinnati, OH) from flash frozen blocks of the pre- 
frontal cortices from Alzheimer's and control brains following the sug- 
gested protocol of the manufacturer. The Northern blot analyses were 
conducted according to the procedure described by DuPont NEN Re- 
search Products (Boston, MA) for Genescreen Plus. In brief, the RNAs 
(60 p.g for each) were separated on a 1% formaldehyde denaturing 
agarose gel and transferred to the GeneScreen Plus nylon membrane, 
and the blot was hybridized with the specific cDNA probe (109 to 2 x 
101° cpm/llg, 106 cpm/p.I). The cDNA probe was labeled with ~2P-dCTP 
(DuPont NEN Research Products) using the Random Primer Kit (Boeh- 
ringer-Mannhein Biochemicals, indianapolis, IN). The blot was subse- 
quently washed and exposed to X-ray film (Kodak). 
G ross loading errors would be unlikely using 60 p.g of RNA; however, 
as an additional oading control, gels were stained with ethidium bro- 
mide prior to transfer to confirm that ribosomal bands were identical 
in thickness and intensity. To detect cross-hybridization or comigration 
of Cat D with the 18S ribosomal species, additional hybridization stud- 
ies were performed using probes for cathepsin B and hexosamini- 
dase A. 
Densitometric Analysis 
Paraffin sections from the prefrontal cortices of Alzheimer's and age- 
matched control brains were analyzed by densitometric analyses. Im- 
mediate adjacent serial sections immunolabeled with anti-Cat D antise- 
rum were hybridized with the specific human digoxigenin-labeled Cat 
D RNA probe (above) to detect mRNA expression using in situ hybrid- 
ization. The sections were coded and analyzed blindly with a user- 
interactive, IBM DEK 486 computer-assisted microdensitometric tech- 
nique. The prefrontal cortices were viewed with a Leitz Laboriux 12 
light microscope interfaced with a Bioquant Meg IV image analysis 
operating system (OS.2 Bioquant version 1.57, R and M Biometrics, 
Nashville, TN) via a Dege MTI CCD-72 solid state digital camera using 
a mouse/keyboard etermination system to outline each neuron. De- 
terminations were done in reversed polarity so that dense areas on 
the slides appeared as light areas on the video monitor. A 100x oil 
immersion objective (nA 1.518) was used to identify pyramidal neurons 
from laminae III and V of the prefrontal cortex (Brodmann Area 10) in 
both immunolabeled and hybridized tissue sections. The image sys- 
tem was calibrated by placing an image box over laminae of interest 
and recording the optical density (expressed as 0-255 levels of gray 
scale; 0, lowest density; 255, highest density). 
A total of 25 small, medium, and large neurons with visibly defined 
nuclei were selected at random from layers ill and V of each brain. 
With the aid of the computer imaging system, the perimeter of each 
neuron was digitized and the area (in square micrometers) recorded. 
For each neuron, a second tracing was made by outlining the nucleus. 
The average optical density representing the total area of the neuron 
and the total area density minus the optical density of the nucleus 
was recorded. For each field, an image box was placed in various 
background regions and the average optical density measured. Statis- 
tical computations were performed using Student's t test. 
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